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Purpose: Advanced triple negative breast cancer (ATNBC) is defined by a lack of expression of hormones receptors
as well as HER2/neu and its high probability of visceral metastasis. This pathology is associated with a poor
prognosis. Previously, we found that T2, an N4-arylsubstituted thiosemicarbazone (N4-TSC), had cytotoxic effect
on human breast cancer cells lines. Hence, in this study, we investigated the anti-metastasic action of T2 on
ATNBC.
Methods: In order to deepen T2 action mode on ATNBC, we first confirmed T2 cytotoxicity on a panel of TNBC
cells and then continued studying T2 effects in vitro an in vivo on the syngeneic 4T1 mouse model.
Results: We found that T2 had a cytotoxic effect comparable to chemotherapeutics used in present treatment
schemes for ATNBC. T2 treatment not only induced apoptosis, but it also down-modulated 4T1 invasive and
metastatic-associated capacities, such as clonogenicity, migration and metallo-proteases activity. Moreover, this
agent reduced the number of 4T1 cancer stem cells. Finally, T2 treatment induced a more differentiated cell
phenotype and the overexpression of the metastasis suppressor gene NDRG-1. In vivo assays showed that T2
reduced tumor burden, down modulated local tumor invasion and significantly reduced the number of lung
metastases in the 4T1 advanced TNBC murine model, while the compound did not exhibit intolerable toxicity.
Conclusion: This study provided evidence that T2 not only exerted an anti-tumor activity but it also showed anti-
invasive and anti-metastatic actions on ATNBC in vivo and in vitro, suggesting that T2 could be considered as a
promising therapy that deserves further analysis.1. Introduction
Breast cancer (BC) is the most frequently diagnosed and the second
main cause of cancer-related deaths amongwomen worldwide [1]. While
a wide spectrum of treatment options is available, the therapeutic choice
depends on its heterogeneous nature [2]. BC is classified into four major
molecular subtypes, considering three biomarkers: Estrogen Receptor
(ER), Progesterone Receptor (PR) and overexpression of human
epidermal growth factor receptor 2 (HER2) [3, 4]. This classification
includes the groups: (i) luminal A (ERþ/PRþ/HER2); (ii) luminal B
(ERþ/PRþ/HER2þ); (iii) HER2þ; and (iv) triple negative (TNBC;allero).
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evier Ltd. This is an open access aER/PR-/HER2). Each of these subtypes has different risk factors for
incidence, therapeutic response, disease progression, and different organ
sites of metastases. Most BC patients (83%) have tumors with hormone
receptors expression, BC patients that are HER2þ constitute only 5% and
TNBC includes the remaining 12% of the total patient population [5].
Advanced triple negative breast cancer is the most aggressive and
difficult subtype to treat. The principal treatment is standard chemo-
therapy, usually consisting of taxanes, anthracycline, and platinum drugs
[6, 7]. Several targeted therapies such as Epidermal Growth Factor Re-
ceptor (EGFR) inhibitors, antiangiogenic agents, DNA repair agents,
checkpoint kinase 1 inhibitors or poly-ADP-ribose-polymerase (PARP)tober 2020
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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substantial improvements in TNBC outcomes have been observed with
these agents [8].
Although, ATNBC is the BC subtype with the most complete response
to chemotherapy (22%), recurrence and metastasis rates for these pa-
tients are higher than for those carrying other BC subtypes [9]. Due to the
lack of receptors expression, the use of targeted therapies in high grade
TNBC tumors is precluded, leaving chemotherapy as the only approved
systemic treatment option. Considering the suboptimal treatment results
with current chemotherapy, new therapies for TNBC are critically
required.
Thiosemicarbazones (TSCs) are iron chelators obtained from a
condensation reaction between a thiosemicarbazide with an aldehyde or
ketone. Among their biologic activities, the anti-tumoral effect has been
recently investigated [10, 11, 12, 13]. The molecular mechanisms
involved in the activity of TSCs have not been completely understood,
however, several modes of action have been reported.
Previously, we reported that two of three studied N4-aryl substituted
thiosemicarbazones (N4-TSC) had cytotoxic effect on a group of different
human breast cancer cell lines. Cell death by apoptosis and necrosis via
ROS formation and ribonucleotide reductase inhibition were the events
observed in response to these N4-TSCs treatment [14].
Taking into consideration the need for ATNBC therapies, in this study,
we explored the action of T2, the most potent N4-TSCs previously studied
and characterized [14], on metastasis and tumor dissemination in vitro
and in vivo in the 4T1 triple negative mouse mammary model that re-
sembles advanced breast cancer [15, 16]. Our results demonstrate that
T2 not only suppressed ATNBC cell growth and induced apoptosis, but it
also down-modulated 4T1 metastasis-associated properties and dimin-
ished cancer stem cell sub-population in vitro. In addition, in vivo studies
demonstrated that this N4-TSC also reduced tumor burden as well as its
local invasiveness and metastatic capacity. These findings describe a
novel activity for T2 and propose this compound as a promising
anti-tumoral and anti-metastasic agent against late-stage TNBC, thus
supporting further investigation.
2. Methods
2.1. In vitro studies
2.1.1. Cell lines
The 4T1 murine mammary cancer cell line was obtained from ATCC
and cultured in RPMI medium supplemented with 10% fetal bovine
serum. LM38-LP cells were isolated from a mammary papillary triple
negative adenocarcinoma that developed spontaneously in a Balb/c
mouse [17]. These cells were grown in DMEM-F12 medium supple-
mented with 10% fetal bovine serum (FBS) and 80 μg/ml gentamycin.
The HCC70 human breast cancer cell line, derived from a primary
ductal triple negative carcinoma and obtained from ATCC, was cultured
in RPMI medium supplemented with 10% FBS. All cell lines were
cultured in 25 cm2 flasks at 37 C in a humidified air atmosphere with
5% CO2.
Cells lines were tested for mycoplasma contamination by DAPI stain
monthly and by PCR every 3 months.
2.1.2. Cytotoxicity assay
Cells grown in 25 cm2 flasks were removed by trypsinization and
seeded into 96-well culture dishes at a concentration of 1,000 cells per
well. Cells were allowed to grow for 48 h at 37 C in a humidified at-
mosphere containing 5% CO2. Then cells were treated with T2 at the
following concentrations: 0.1, 1, 10, 25, and 50 μM or with DMSO (0.1%)
(control) for additional 120 h 4T1 cells were also treated with Cisplatin
or Paclitaxel with the same concentration as T2. Cell viability was
determined by the MTS method [18]. The IC50 were determined through
non-linear regression analysis using the concentration log-response curve
for each cell line employing PrismGraph software.2
2.1.3. Colony formation assay
4T1 cells treated with T2 (2.5, 5 or 10 μM) or DMSO 0.02% (control)
for 24 h, were harvested with trypsin-EDTA and counted manually in the
presence of Trypan blue. Then, cells were diluted and seeded at about
1,000 viable cells per well of a six-well plate. After incubation for 7–10
days, cells were washed twice with PBS, fixed with methanol:acetic acid
for 15 min, and stained with 0.5% crystal violet for 15 min at room
temperature. A colony was defined to consist of at least 20 cells. Colonies
were counted under a stereoscopic microscope. Clonogenic capacity was
calculated with the following formula:
Clonogenic Capacity¼ number of colonies=number of seeded cells
2.1.4. Quantification of apoptosis
Apoptotic/necrotic cells were determined by Annexin V-FITC and
propidium iodide staining. To do so, cells were seeded in six-well plates,
treated with T2 (2.5, 5 or 10 μM) or DMSO 0.02% (control) for 48 h, and
washed. Then, cells were removed by trypsinization and stained. Fluo-
rescence was measured by flow cytometry and analyzed using Cyflogic
software version 1.2.1.
Western blot analyses using antibodies against caspase 3 (Cell
Signaling #9662S 1:1000), poly(ADP-ribose) polymerase (PARP) (Cell
Signalling #9532S, 1:1000) and Bcl-XL (Abcam #ab322370, 1:1000)
were performed using total lysates of 4T1 cells treated with T2 or DMSO
as previously described. Actin was used as loading control.
2.1.5. Wound healing assay
4T1 cells were seeded in six-well plates and incubated for 48 h to
achieve an 80–90% confluent monolayer. Cells were treated for 24 h with
2.5, 5 or 10 μM T2. After this time had elapsed, a single scratch wound
was created in the monolayer with a yellow tip. The wound was photo-
graphed under a phase contrast microscope at time 0 and approximately
17 h later (final time, Tf). Cell migration was assessed by determining the
covered area at T0 and Tf in four fields per well with ImageJ software;
then the percentage of migration was calculated using the following
equation:
ðTf T0Þ =T0
2.1.6. Gelatin zymography assay
Activity of metaloproteinases (MMPs) was analyzed by a gelatin
zymography assay as previously described [19]. Cells were seeded in
6-well plates and grown for 48 h in medium containing 10 % FBS. Then,
cells were treated with DMSO or T2 (2.5, 5 or 10 μM) for 24 h. The cell
conditioned media were electrophoresed in a 10 % polyacrylamide gel
containing 0.1 % gelatin. After electrophoresis, the gel was incubated at
37 C overnight in a buffer (50 mM Tris, pH 8.0, 10 mM CaCl2 and 1 mM
ZnCl2) to facilitate gelatin degradation by gelatinase. The gel was washed
with water and subsequently stained with 0.5 % Coomassie brilliant blue
R250 and destained in destaining solution (methanol:acetic acid:water in
the ratio of 4:1:5). Gelatinase activity was measured densitometrically
after scanning the gel. Bands were quantified in arbitrary units using
Image J and relativized to total protein content.
2.1.7. Transwell invasion assay
4T1 cells treated with T2 (2.5, 5 or 10 μM) or DMSO (control) for 24 h
were seeded on transwell chambers (8 microns’ pore size) coated with
Matrigel [20]. Then cells were stimulated by filling bottom reservoir with
medium containing 10% FBS for 5 h. Membranes were fixed, stained with
DAPI, observed under fluorescence microscope and then imaged to
quantify the number of cells that migrated to the bottom side of the
membrane.
2.1.8. Mammosphere formation assay
4T1 cells treated with T2 (2.5, 5 or 10 μM) or DMSO 0.02%
(control) for 24 h were trypsinized and grown in suspension in six-
A.M. Solimo et al. Heliyon 6 (2020) e05161well low attachment culture plates at a density of 5,000 viable cells/
ml in the presence of serum-free media supplemented with B27 and
EGF. Resulting mammospheres were manually counted after 5–8 days
in culture using a Nikon eclipse TE2000-S phase contrast inverted
microscope. Mammospheres were also imaged and photographed
under the same microscope. Diameters were measured with Image J
software. Fifteen to twenty fields per plate were used to calculate
diameter average of mammospheres.
2.1.9. In vitro treatment of mammospheres
4T1 cell were used to generate mammospheres as previously
described. After 5–8 days, mammospheres were exposed to T2 T2 (2.5, 5
or 10 μM) or DMSO (control) for 24 h and visualized under Nikon eclipse
TE2000-S phase contrast inverted microscope.
2.1.10. Flow cytometry analyses for cancer stem cell sub-population
Treated 4T1 cells were harvested and resuspended in PBS following
staining to detect CD24-APC, CD29-FITC and LIN-PE employing the
PASIII (PARTEC) cytometer. Population analysis was made using FlowJo
software.
2.1.11. Evaluation of pluripotent genes expression
Total RNA from 4T1 cells treated with T2 (2.5, 5 or 10 μM) or DMSO
0.02% (control) for 24 h was isolated using Trizol Reagent. RNA con-
centration was estimated by measuring the optical density at 260 nm and
2 μg RNA was reversely transcribed by using M-MLV Transcriptase (1U)
and random hexamers (50 ng/μl). Real-Time PCR for Nanog, Oct-4 and
Sox-2 was performed in a 20 μl master mixture of TransStar Green Kit and
specific primers were used at 0.25 μM. Real-Time PCR reactions were
performed in a C1000 Thermal Cycler (Biorad) and the amplification
program consisted of an initial denaturing step (94 C for 5 min), fol-
lowed by 40 cycles (each of 94 C for 30 s, 60 C for 30 s and 72 C for 30
s). Sample quantification was normalized to endogenous GAPDH that
was also quantified by Real-Time PCR, following the same protocol as
that for pluripotent genes. Fluorescence signal acquisition was carried
out at the end of the elongation step. Each assay included a DNA minus
control. All samples were run in duplicate and the experiment repeated
3x with independently isolated RNA. RNA expression changes were
calculated using the 2ΔΔCt method.
2.1.12. Evaluation of NDRG-1 and E-cadherin expression
4T1 cells were treated with T2 (2.5, 5 or 10 μM) or DMSO 0.02%
(control) for 24 h. Total RNA extraction and reverse transcription were
performed as previously described. Real time PCR for NDRG-1 was car-
ried out using specific primers and the amplification program consisted
of an initial denaturing step (94 C for 5 min), followed by 40 cycles
(each of 94 C for 30 s, 56 C for 30 s and 72 C for 30 s). Sample
quantification was normalized to endogenous GAPDH which was also
quantified by Real-Time PCR [21], following the same protocol as that
for NDRG-1. Fluorescence signal acquisition was carried out at the end of
the elongation step. Each assay included a DNA minus control. All sam-
ples were run in duplicate and the experiment repeated 3x with inde-
pendently isolated RNA. RNA expression changes were calculated using
the 2ΔΔCt method.
For protein expression, confluent monolayers of 4T1 cells previously
treated with T2 (2.5, 5 or 10 μM) or DMSO 0.02% (control) for 24 h were
washed three times with ice cold PBS and then lysed with Lysis Buffer
(RIPA with EDTA) containing protease inhibitors cocktail. Protein con-
tent of cell samples was determined by Bradford method [22]. The
samples were boiled in Laemmli sample buffer with 5% β-mercaptoe-
thanol. Western Blot analyses were carried out using SDS-PAGE. Elec-
trophoresis gels were transferred to PVDF membranes. Non-specific
binding was blocked by incubation of the membrane with TBS 5% skim
milk for an hour. Then, membranes were incubated with the specific
antibodies against NDRG-1 (Santa Cruz, sc-398291, 1:1000) or E-cad-
herin (Abcam, #ab76055, 1:1000) overnight at 4 C.3
2.1.13. Immunofluorescence
Cells were grown on glass coverslips and treated with T2 (2.5, 5 or 10
μM) or DMSO 0.02% (control). After 24 h, cells were fixed in 4% form-
aldehyde/PBS at room temperature for 15 min, permeabilized and
blocked with PBS 5% SFB þ 0.3% triton for 90 min at 37 C. Smooth
muscle actin (SMA) was detected by incubation with a primary mono-
clonal antibody (Sigma #120M468, 1:500), followed by incubation with
an anti-mouse IgG-Alexa 488 secondary antibody (1:500) for 1 h (Invi-
trogen-Thermo Fisher Scientific). Nuclei were stained with propidium
iodide. Images were obtained in an Olympus Fluo view FV 1000 micro-
scope. The quantitative microscopy measurements were performed in
individual cells (13–745 cells for each treatment or condition). Confocal
microscope images were processed with FIJI (https://fiji.sc). Channel
backgrounds (mean of empty region) were substracted. Segmentation of
the nuclear compartment was performed for each cell using the IP signal.
For F-Actin staining, coverslips were incubated for 45 min at RT with
phalloidin-FITC (Sigma-Aldrich, 1:400) and cell nuclei were counter-
stained with DAPI. The coverslips were mounted with Mowiol 4–88
(Calbiochem). Cells were imaged by confocal laser scanning microscopy,
which was performed with the same microscope but using an Olympus
60/1.20 NA UPLA APO water immersion objective and a 3x digital
zoom. Graphic depiction was then generated where the x-axis repre-
sented the distance across the cell and the y-axis represented the level of
fluorescence. Twelve cells were randomly selected from each group of
treatment for graphic depicting.
2.2. In vivo studies
2.2.1. Animals
Inbred 3–4 month old BALB/c female mice (20–25 g body weight)
were obtained from the Animal Care Division of the Research Area of the
Institute of Oncology "Angel H. Roffo". All applicable international, na-
tional, and/or institutional guidelines for the care and use of animals
were followed. Specific protocols used in this study were approved by the
Angel H. Roffo Institute IACUC (approved protocol number 2017/01).
2.2.2. Determination of the maximum tolerated dose (MTD) in control
healthy BALB/c mice
The starting dose of T2was determined by a review of the literature in
which other thiosemicarbazones were used [10, 23]. The MTD was
defined as the dose level at which 30% or less of a cohort either died or
lost weight in excess of 10%. Cohorts of 5–10 BALB/c mice were used in
toxicity experiments and received T2 (5, 25 or 50 mg/kg) or equal vol-
umes of 0.9% NaCl solution or vehicle (saline solution with 17% DMSO
and 30% propilenglycol) to determine the MTD. Treatments were given
i.p., 5 times every two days. Mice were monitored daily and weighted
every 3 days. After necropsy, blood samples were collected and serum
concentrations of urea and glutamic oxaloacetic transaminase (GOT or
AST) were determined. The blood samples were also used to determine
erythrocyte and leukocyte counts, hemoglobin and hematocrit. The he-
matological analyses were performed in the clinical analysis laboratory
of our institute. The values obtained were compared within and between
groups. At the end of the experimental period (30 days) histopathological
analyses of the lungs, liver and kidneys were performed.
2.2.3. Tumor growth and spontaneous metastases capacity
4T1 cells (3,5 x 104) were injected subcutaneously and after one week
T2 treatment was initiated. For animal dosing, T2 was prepared as a
smooth suspension in saline solution containing 17% DMSO and 30%
propilenglycol. Each experiment (n ¼ 18 mice) contained a vehicle
control group treated in parallel with the T2-treated groups. T2 was
evaluated at two dose levels (n ¼ 6 mice per dose) given intraperitone-
ally. The treatment schedule comprised 5 doses once a day administered
day through. After 25–30 days, animals were euthanatized, and tumors
were weighed and then fixed in formaldehyde. Lungs were removed and
fixed with Bouin's solution. Spontaneous metastatic nodules were
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formed three times.
2.2.4. Experimental metastases
4T1 cell monolayers treated with T2 (2.5, 5 or 10 μM) or DMSO
0.02% (control) for 24 h were trypsinized, resuspended in serum free
RPMI and injected into the tail vein of BALB/c mice at 4  104 cells/100
μl. After three weeks, mice were sacrificed, and lungs were fixed in
Bouin's solution. Superficial metastatic nodules were observed, imaged
and counted under stereoscopic microscope.
2.2.5. Histopathological analysis
For the histopathological analysis, lungs, liver, kidneys and tumors
were collected and fixed by immersion in a 10% buffered formaldehyde
solution for 24h, followed by dehydration in increasing concentrations of
alcohol, incubation in xylol and soaking in paraffin. The sections were cut
to 5 μm thickness and stained with hematoxylin and eosin (HE) or
Masson's Trichrome for histopathological analysis. Mitotic figures were
counted under microscope (Magnification 400 x). Histopathologic anal-
ysis was done by external accredited experimental pathologists.
2.2.6. Statistical analyses
Differences between groups were analyzed using one-way ANOVA
with Tukey's test or the Tukey–Kramer multiple comparison test for
evaluating three or more groups. For in vivo assays, statistical signifi-
cance was determined using non-parametrical analyses with comparisons
by Kruskal–Wallis, Dunn's post test. Statistical analysis was performed
using GraphPad Prism 4.0, Graph Pad software, Inc. San Diego,Figure 1. T2 reduces cell viability in triple negative breast cancer cell lines a
results from MTS viability assays examining the effects of T2 on the growth of 4T1, LM
5 days. (C) Cell apoptosis determined by Annexin V-FITC and propidium iodide sta
incubation with T2 (2.5, 5 and 10 μM) or DMSO (control). Results are expressed as m
cleavage, caspase-3 activation and Bcl-xL induction after T2 (2.5, 5 and 10 μM) or D
Densitometric analyses of three independent western blots.
4
California, USA, www.graphpad.com. Differences were considered sig-
nificant at p < 0.05.
3. Results
3.1. T2 induces 4T1 cell death by apoptosis
Considering the need to find new therapies for metastasic advanced
TNBC, we decided to deepen the study of the action of T2 on this breast
cancer subtype. Therefore, we first confirmed its effects in vitro on a triple
negative breast cancer cells panel composed by the murine 4T1 and
LM38-LP cell lines and the human HCC70 cell line.
As Figure 1B shows, when we compared cell viability in TNBC cell
lines after T2 treatment in a dose range between 0 and 50 μM, we
observed a potent cell growth inhibition on all cell lines. The concen-
tration of T2 required to reach 50% of control untreated cells was 5.9 μM,
3.16 μM and 3.40 μM for 4T1, LM38-LP and HCC70 cells, respectively.
Besides, after treating 4T1 cells with Cisplatin or Paclitaxel, we found
comparable IC50 values for these two current treatments for TNBC (6.21
μM and 6.32 μM, respectively, data not shown). Considering 4T1 as a
representative advanced triple negative model, and taking into account
the certain possibility of developing in vivo assays in syngeneic mice, we
decided to continue our experiments with this cell line using the estab-
lished T2 concentrations of 2.5, 5 y 10 μM.
Flow cytometry analysis of cells treated with T2 for 48 h and stained
with Annexin V and propidium iodide revealed that T2 lowest concen-
tration used was enough to cause a significant increase in the number of
both early and late apoptotic cells compared to control cells treated withnd induces apoptosis. (A) T2 formula. (B) Concentration log-response curve:
38-LP and HCC70 cell lines. Cells were incubated with T2 or DMSO (control) for
ining. Flow cytometer analysis of the apoptotic and necrotic cells after 24 h of
ean  standard deviation, *p < 0.05 (n ¼ 3). (D) Western blots illustrating PARP
MSO (control) treatment for 24 h. A representative blot of three is shown. (E)
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4T1 cells to death by apoptosis (Figure 1C).
To further investigate T2 effect on 4T1 cells death, we carried out
Western Blot experiments upon separated proteins of whole cell lysates
following treatment with T2 during 48 h. As seen in figures 1D and E,
treatment with T2 induced caspase-3 activation, observed as an increase
in proteolytic processing of its inactive zymogen into the activated p17
fragment. In accordance with this result, PARP cleavage, and Bcl-XL
expression downregulation were observed after T2 treatment. Full,
non-adjusted images are shown in supplementary material.3.2. T2 reduces the clonogenicity, migration and invasiveness of 4T1 cells
Previously we have observed that T2 reduced clonogenicity and
migration in MDA-MB231 cells [14]. In order to analyze whether T2
exerted similar actions on 4T1 cells, the anticancer activity of T2 was
further studied using a short 24h-treatment, an experimental condition
that did not show cell cytotoxicity. First, we performed a clonogenic
assay. As shown in Figure 2A, T2 treatment during 24 h induced a sig-
nificant inhibition of colony formation starting at the concentration of
2.5 μM and showing a dose-dependent modulation.
Since tumor cell migration and invasiveness are key determinants in
tumor progression and metastatic dissemination, we tested whether T2
modulates the migration ability of 4T1 cells by performing a wound-
healing assay. We observed a significant decrease in the cells capacity
to close the wound with the three assayed concentrations of T2
(Figures 2B and C).
Considering that matrix metalloproteases are enzymes with a relevant
role in cell invasion, we studied the activity of the matrix metalloprotease
2 and 9 (MMP2 and MMP9, respectively) through zymograms
(Figure 2D) and found that MMP9 activity was significantly reduced after
treating 4T1 cells with 10 μM T2 for 24 h while MMP2 activity was not
modulated by T2. Full, non-adjusted images are shown in supplementary
material. Taking into account that one of the factors relevant for the
invasive process was altered by T2 treatment, wewent on to further study
this aspect using transwell chambers coated with Matrigel and FBS in the
lower compartment used as chemoattractant. T2 treatments significantlyFigure 2. T2 downmodulates metastasis-related properties of 4T1 cells (A) Clono
DMSO (control) for 24 h. The values represent the mean of three independent experim
4T1 cells were treated with T2 (2.5, 5 and 10 μM) or DMSO (control) for 12 h. The
significantly different from controls are indicated *p < 0.05 or **p < 0.01, (magni
Representative fields from one migration experiment are shown. (D) Zymogram assay
(2.5, 5 and 10 μM) or DMSO (control) for 12 h and conditioned media were run. U
analyses of MMP-9 activity. Data represent the relation between the optical density
pendent experiments, **p < 0.01 respect to control cells. (E) Invasion capacity was an
Left panel: Results are expressed as mean  standard deviation (n ¼ 3). Right p
(Magnification 100, scale bar 40 μm).
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reduced the invasive capacity of 4T1 cells to reach the filters after
degrading the Matrigel (Figure 2E).3.3. T2 diminishes cancer stem cells (CSC) sub-population of 4T1 cell line
In order to determine whether T2 could affect 4T1 CSCs, we per-
formed a mammosphere forming assay using 4T1 cells previously treated
with T2 for 24 h. As shown in Figure 3A, 5 and 10 μM T2 caused an
evident reduction in mammosphere number (left) and a significant
decrease in mammosphere size (right). Consistent with these results, we
observed a decrease in the percentage of 4T1 cells that expressed high
concentration of CD29, a CSCmarker (Figure 3B.) In addition, we found a
lower expression of the pluripotency associated genes Nanog, Oct-4 and
Sox-2 in T2 treated cells, compared with untreated control cells
(Figure 3C). Since a 24h treatment with T2 did not induce cytotoxicity,
downregulation of these genes expression could be associated with a
smaller population of stem cells.
We then sought to determine T2 action on already formed mammo-
spheres. Treatment with T2 showed a direct cytotoxic effect, observed by
a spheres disruption. Mammospheres were dissociated and reduced in
number at concentrations of 5 and 10 μM of T2 (Supp. Figure 1), sug-
gesting CSCs cell death induced by T2.3.4. T2 decreases experimental metastatic capacity of 4T1 cells
In the metastatic process, upon cells detachment from the tumor, their
capacity to survive in the blood stream and colonize other tissues is
crucial. In order to assess this key aspect, we performed an experimental
metastasis assay. Cells were pre-treated ex-vivowith T2 for 24 h and then
inoculated intravenously in BALB/c mice. Three weeks later, mice were
euthanized and the number and size of superficial metastatic nodules in
their lungs were recorded We found that the total number of metastatic
nodules was significantly reduced when cells were pre-treated with 5 and
10 μMT2 (Figure 4). . Similarly, when nodules were distributed by size, 5
and 10 μMT2 showed a significant reduction of metastatic nodules larger
than 0.5 mm diameter (Supplementary Figure 2).genic assay was done with 4T1 cells pre-incubated with T2 (2.5, 5 and 10 μM) or
ents, *p < 0.05 or **p < 0.01 with respect to control cells. (B) Migration assay:
graph shows the migration percentage for each T2 treatment. Values that are
fication 200, scale bar 40 μm) Experiments were performed in triplicate. (C)
was used to evaluate MMP9 gelatinase activity: 4T1 cells were treated with T2
pper panel: Representative gelatin zymography gel. Lower panel: densitometric
and total protein concentration. The values represent the mean of three inde-
alyzed by a Transwell chamber assay. Cells were treated as previously described.
anel: representative micrographs from one of three independent experiments
Figure 3. T2 reduces CSC subpopulation in 4T1 cells. Cells were treated with T2 or DMSO (control) for 48 h. (A) Mammospheres number and size (diameter) were
evaluated after a 5–8 days culture in mammosphere formation conditions. Data represent the mean of at least three independent experiments, *p < 0.05 or **p < 0.01
with respect to control cells. (B) Flow cytometry for Lin(-)/CD29h/CD24(þ) expression in 4T1 cells. Data are the mean of at least three independent experiments. *p <
0.05 or **p < 0.01 compared to control untreated cells. (C) Expression of pluripotential genes analyzed by real time PCR. Results are expressed as mean  standard
deviation (n ¼ 3), *p < 0.05 with respect to control cells.
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It has been reported that human NDRG-1 (N-myc down regulated
gene), could act as a metastasis suppressor in several types of cancer
[24, 25]. In addition, NDRG-1 expression was reported to be
up-regulated by other thiosemicarbazones such as Dp44mT and DpC
[23]. Moreover, breast cancer metastasis was reported to be inhibited
by Dp44mT in vivo, which effect was dependent on its ability to
up-regulate NDRG-1 [26]. Therefore, we evaluated NDRG-1 expres-
sion at mRNA and protein levels. As Figure 5A shows, we found that
while T2 did not alter NDRG1 mRNA expression, it induced an in-
crease in the amount of protein. Full, non-adjusted images are shown
in supplementary material.
3.6. T2 induces a less undifferentiated phenotype in 4T1 cells
In cancer, poor cell differentiation is usually related with a worse
prognosis. While the most differentiated epithelial cells show less inva-
sive capacity and a higher expression level of adherence proteins such as6
E-cadherin, the undifferentiated fibroblastoid-like cells are commonly
invasive and express lower levels of these proteins.
T2 treatment up-regulated E-cadherin while the expression of the
myofibroblastic marker alpha smooth muscle actin (SMA) was reduced as
shown both by western blot and confocal microscopy (Figure 5B and 5C,
respectively). Moreover, a cortical reorganization of actin distribution
was observed after staining the actin filaments of cells treated with T2 for
24 h with phalloidin-FITC (Figure 5D) evidencing a more differentiated
epithelial phenotype.
3.7. T2 has anti-tumor and anti-metastatic action in vivo
To further characterize the efficacy of T2 against triple negative
breast cancer and its potential as a promising anti-tumor agent, further
studies examining this agent were performed in vivo.
In order to choose the appropriate doses to perform the antitumor
studies in mice, we first evaluated the maximum tolerated dose of T2 and
its acute toxicity as described in materials andmethods (2.2). The highest
concentration of T2 (50 mg/kg) caused death to 1/3 of the animals, so it
Figure 4. T2 downmodulates the experimental metatastic ability of 4T1 cells. 4T1 cells treated in vitro with T2 or DMSO (control) for 48 were injected
intravenously in BALB/c mice and the number of total experimental lung metastases was recorded after 21 days. (A) Data represent metastatic nodules median and
range of one representative experiment of three independent assays. *p < 0.05 respect to control cells. (B) Representative photograph of lung metastatic foci.
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and showed no severe clinical side effects with no mortality. Further-
more, changes either in behavior or body weight of the animals
throughout the experiment were absent (Supplementary Figure 3A).
The observed hematological parameters of animals treated with T2
were within the reference limits and full hematological analysis showed
no difference respect to vehicle treated mice (Data not shown).
Biochemical analysis of blood taken from animals treated with T2 did not
show any alteration either in urea concentration or in the enzyme glu-
tamic oxaloacetic transaminase (AST-TGO), indicating the absence of7
renal and hepatic alterations in the animals of this group (Supplementary
Figure 3B and 3C, respectively). Histopathological studies on the liver,
heart, kidneys and lungs were performed to determine the presence of
pathological alterations caused by T2. The results indicate that there was
no alteration in the organs from the treated groups compared with the
control.
Therefore, in order to evaluate T2 action in vivo, treatment consisted
of five doses of vehicle or T2 (5/25 mg/kg) administered intraperitone-
ally every other day. Tumor weight, measured after necropsy, showed
that tumors of control untreated mice reached a weight of 522,6  100
Figure 5. T2 induces NDRG-1 protein expression and a more differentiated phenotype in 4T1 cells. (A) RNA from T2 treated or control untreated 4T1 cells was
isolated. The expression of NDRG-1 was evaluated by Real Time PCR. Data represent the media and standard error of three independent experiments. (B) Lysates from
T2 or DMSO treated 4T1 cells were prepared, and their total protein content was subjected to SDS-Page and Western blot. Representative NDRG-1 and E-cadherin blots
are shown. Tubulin was used as loading control. (C) Immunofluorescence micrograph of αSMA expression (Magnification 600, scale bar 10 μm) and fluorescence
intensity quantification of T2 or DMSO treated 4T1 cells. Nuclei were stained with propidium iodide. Data represent median and range of three independent ex-
periments. *p < 0.05 respect to control cells (D) Fluorescence microscope analysis of actin cytoskeleton after phalloidin-FITC staining of T2 or DMSO treated 4 T1 cells
Nuclei were stained with DAPI. Representative images are shown (Magnification x1000, scale bar 10 μm). The scatter plots represent the quantification of fluorescence
intensity across the lines of 10 cells of each group using ImageJ software.
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weight (Figure 6A). In accordance, the average number of mitotic figures
in tumors of T2 treated mice was lower than in control ones (Figure 6B).
The 4T1 tumor is a mammary adenocarcinoma with an aggressive
fast-growing behavior which develops metastatic disease spontaneously
from the primary tumor like triple negative BC in humans does. More-
over, the progressive spread of 4T1 metastases to the draining lymph
nodes and other organs resemble that of human BC. Interestingly, after
necropsy, we found that although 63 3% of control tumors were able to
invade the abdominal muscle wall and parietal peritoneum, and then
colonize the peritoneal cavity of mice, only 40.0 1.0% and 22.5 2.5%
of T2-treated ones (5 and 25 mg/kg, respectively) had this ability
(Figure 6C). Moreover, microscopic examination of the tumor revealed
infiltrative edges in control mice tumors with disruption of collagen fi-
bers distribution (pointed with an arrow). However, in T2 treated mice
tumors, there was less evidence of invasion with less expansive edges and
collagen fibers appeared more straight and aligned parallel to the tumor8
border (Figure 6D). With respect to blood dissemination, the T2 treated
mice developed a significantly lower number of spontaneous lung me-
tastases per mouse compared with control untreated mice (Figure 6F).
4. Discussion
Advanced triple negative cancer is considered as one of the most
frequent causes of cancer-related mortality in women worldwide [1].
Moreover, it is the most aggressive and challenging to treat among breast
cancers. Although TNBC shows the most complete response to chemo-
therapy, among different breast cancer subtypes, patients with late-stage
TNBC tumors have a less satisfactory prognosis than those with other
breast cancer tumors. In addition, most patients with advanced TNBC
succumb to metastasis. Increasing researches suggest that iron chelators
can be used as new anti-cancer drugs accomplishing critical impact in
different cancers treatment [27, 28, 29]. In this context, we have previ-
ously demonstrated that two N4-aryl substituted thiosemicarbazones had
Figure 6. In vivo treatment with T2 inhibited 4T1 tumor growth, invasion and metastasis. 3.5 x 104 4T1 cells were injected subcutaneously into female BALB/C
mice. After one week mice were injected intraperitoneally with vehicle (control) or T2 (5 or 25 mg/kg of body weight) 5 times every two days (n ¼ 6 mice per group)
as described in materials and methods. (A) Tumor weight after necropsy. Plot of a representative experiment of three independent assays, *p < 0.05 respect to control
cells. (B) Number of mitotic figures per ten analyzed fields, counted under microscope from hematoxylin-eosin stained tumor sections. Data represent the media and
the standard error of three independent experiments, ***p < 0.001 respect to control cells. (C) Illustrative examples of differential peritoneal invasion and (D)
hematoxylin-eosin (H&E) and Masson's Trichromic staining of tumors are shown. Arrow points tumor edge (Magnifications 100 (left pannel) and 200 (right panel),
scale bar 200μm). (E) Number of spontaneous lung metastases. Each value corresponds to the median and range of a representative experiment of three independent
assays, *p < 0.05 respect to non-treated mice.
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expression of ER, PR and Her2/NEU. In the present study, we investi-
gated the effect of T2, the most potent N4-TSC, on metastasis in vitro and
in vivo.
Our first results confirmed that T2 had cytotoxic activity on TNBC,
since its effects on HCC70, LM38-LP, and 4T1 TNBC cell lines were
similar to those found in our previous study [14]. Moreover, the cytotoxic
effect of T2 on 4T1 cells was as potent as that observed for Cisplatin and
Paclitaxel, chemotherapy agents currently used in first-line therapy for
TNBC at present. Next, in vitro 4T1 studies suggested that T2 cytotoxic
effect was reflected in an increase in apoptosis via caspase-3 activation
and a decrease in its clonogenic capacity.
Our next objective was to study whether this N4-TSC was also able to
modulate the remarkable capacity of advanced TNBCs to metastasize,
therefore we selected the 4T1model for the following experiments, for its
capacity to grow and disseminate in syngeneic mice and to progress quite
similarly to human late-stage breast cancer.
Cell migration and invasion are critical phenomena in cancer cells
metastatic dissemination. These processes require degradation of the
connective tissue associated with the vascular basal membrane (BM) and
interstitial connective tissue [30, 31]. Therefore, invasion through a BM
is a crucial step in metastasis [32]. By wound healing and invasion
transwell assays, the present study demonstrated that T2 significantly
inhibited the migration capacity and invasiveness of 4T1 breast cancer
cells in a dose-dependent manner.
Prior to cell invasion through basement membrane barriers, proteo-
lytic degradation is crucial. Several classes of extracellular matrix (ECM)-
degrading enzymes are responsible for BM and ECM degradation. MMPs
are one important class of structurally related ECM-degrading enzymes
[33] that are highly regulated and capable of cleaving most of the
components of ECM. Consequently, MMPs have been involved as possible
links between invasion and metastasis in several tumor models [34, 35,
36, 37]. By zymography assay, we found that T2 inhibited MMP-9
gelatinase activity in 4T1 cells.
Cell motility and consequently metastasis ability are critically
dependent on tightly controlled remodeling of actin cytoskeleton. In9
agreement, our results showed that T2 induced an actin cortical dispo-
sition suggesting the change to a more differentiated epithelial pheno-
type. Further analyses revealed that T2 also increased E-cadherin
expression while it reduced αSMA, supporting the hypothesis that T2
treatment may be driving 4T1 cells to a mesenchymal-epithelial transi-
tion (MET). We expect that ongoing studies on intermediates such us
ZEB1 and Twist will confirm T2 involvement in this process.
CSCs comprise a minor sub-population of almost quiescent cells in the
tumor that have the ability to self-renew and differentiate into non-stem
daughter cells which would be part of the tumor [38, 39, 40]. Fast
proliferating cells are the principal targets of chemotherapy and radio-
therapy. Since CSCs remain in the quiescent stage of the cell cycle most of
the time [41, 42], they can avoid the damage caused by chemothera-
peutic drugs, unlike the rapidly dividing cells, so CSCs survive and then
raise recurrent tumors, frequently at metastatic sites [43]. Consequently,
drugs with deleterious effects against CSCs should inhibit tumor growth,
metastasis, recurrence, and drug resistance. In this study, we demon-
strated that T2, a supposed iron chelator, reduced the number of CSCs
present in 4T1 cell line and that it also showed a direct cytotoxic effect on
CSC mammospheres derived from 4T1 cells. In 2006, Shackleton et al.
identified a subpopulation of mammary cells, classified as Lin- (negative
for endothelial marker CD31 and hematopoietic markers CD45 and
TER119), CD29high (β-1 integrin) and CD24þ (a heat-stable antigen
expressed on human breast tumors), from which a single cell could
differentiate into complex alveolar-like structures that produced milk
protein, demonstrating the ability of these cells to reconstitute a com-
plete mammary gland [44]. Therefore, we also evaluated
Lin/CD29h/CD24þ cells after T2 treatment and found that T2 reduced
this population in 4T1 cell line. Gene expression is also a major consid-
eration when investigating CSCs, with Oct4 (octamer-binding transcrip-
tion factor 4), Sox2 (sex determining region Y-box 2), and homeobox
protein Nanog being recognized as master transcription factors (TFs)
controlling pluripotency [45]. Thus, we further studied pluripotency
genes expression detecting a lower level in 4T1 cells, after T2 treatment.
These results agree with Ninomiya et al [46], who demonstrated that iron
A.M. Solimo et al. Heliyon 6 (2020) e05161appears to be crucial for the proliferation and maintenance of stemness of
CSCs.
Taking into account all the effects shown in vitro by T2 on metastasis-
related properties, we developed an experimental metastasis assay in vivo
with 4T1 cells. In accordance, our results showed that T2 ex-vivo pre-
treatment of 4T1 cells significantly reduced the number of lung meta-
static nodules developed 21 days after iv inoculation.
Considering that metastasis is a complex process that demands the
modulation of both metastasis-promoting and metastasis suppressor
genes, and since NDRG-1 (N-myc downregulated gene 1) is a potential
molecular target for cancer therapy regulated by novel thio-
semicarbazones [23, 47], we analyzed its modulation after T2 treatment
in the same cells. At mRNA level, we observed that T2 did not induce any
variation in NDRG-1 expression. However, T2 significantly increased its
expression in a dose-dependent manner at protein level, indicating that
T2 treatment somehow modulated the translational process. Future
studies including protein synthesis inhibition by protein interactions and
miRNAs must be done to explore and determine which is the mechanism
responsible of this translation modulation.
Finally, further in vivo experiments demonstrated that the intraperi-
toneal administration of T2 reduced the growth of 4T1 tumor without
any acute or chronic toxicity observed at the assayed doses. Macroscopic
and microscopic observations also showed that T2 reduced in vivo tumor
invasiveness. Considering that distant metastasis is the major cause of
death in TNBC, we also investigated T2 effect on 4T1 spontaneous met-
astatic capacity and we found that this N4-TSC significantly reduced the
metastasic nodules in T2-treated mice lungs. This anti-metastasic action
of T2 could represent an important advantage over first line chemo-
therapeutics such as paclitaxel, which has shown to elicits a proin-
flammatory effect dependent on Toll-like receptors (TLRs) signaling that
results in cancer treatment failure, tumor resistance or even induction of
the lymph node and pulmonary metastasis of breast cancer [28, 29].
In conclusion, new drug therapies able to overcome existing problems
of drug resistance, recurrence and metastasis are urgently required for
advanced TNBC. We have been recently exploring the activity of a group
of Fe chelators as potential cancer treatment. The best performing
chelator, T2, showed in vitro pronounced cytotoxic activity against a
panel of triple negative breast cancer cell lines including 4T1, LM38-LP
and HCC70 cells. Besides, this TSC notably down-modulated 4T1
metastatic-associated properties. Intraperitoneal T2 administration in
BALB/c mice showed a remarkable growth inhibition of the syngeneic
4T1 late-stage tumor without evident toxic effects in the host. It was also
demonstrated that this N4-TSC significantly reduced in vivo 4T1 tumor
invasiveness and metastasis. Finally, our findings highlight T2 as a
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